{"id":29290,"date":"2025-08-01T19:59:45","date_gmt":"2025-08-01T19:59:45","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/energenesis-biomedical-announces-positive-phase-i-results-for-energi-f705pd-a-potential-disease-modifying-treatment-for-parkinsons-disease\/"},"modified":"2025-08-01T19:59:45","modified_gmt":"2025-08-01T19:59:45","slug":"energenesis-biomedical-announces-positive-phase-i-results-for-energi-f705pd-a-potential-disease-modifying-treatment-for-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=29290","title":{"rendered":"Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson&#8217;s Disease"},"content":{"rendered":"<ul type=\"disc\">\n<li>The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational drug in 24 healthy subjects.<\/li>\n<li>The results confirmed the favorable safety and tolerability profile of ENERGI-F705PD and successfully validated its sustained-release oral formulation.<\/li>\n<li>Energenesis plans to advance ENERGI-F705PD into a Phase II trial.<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">TAIPEI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 1, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company focused on cellular energy restoration therapeutics, today announced the successful completion of its Phase I clinical trial for ENERGI-F705PD, an oral investigational drug candidate for Parkinson&#8217;s disease (PD). The Phase I study demonstrated favorable safety and tolerability in healthy volunteers, marking a significant milestone in the development of ENERGI-F705PD and reaffirming its potential as a disease-modifying therapy that targets intracellular alpha-synuclein aggregation. Energenesis Biomedical plans to submit a Phase II clinical trial application in 2025 to further evaluate the therapeutic efficacy of ENERGI-F705PD in patients with Parkinson&#8217;s disease.<\/p>\n<p>&#8220;Current treatments for Parkinson&#8217;s disease primarily target symptoms, while ENERGI-F705PD represents a novel therapeutic strategy with disease-modifying potential,&#8221; said <b>Dr. <span class=\"xn-person\">Han-Min Chen<\/span>, CEO &amp; Founder of Energenesis Biomedical<\/b>. &#8220;ENERGI-F705PD targets Parkinson&#8217;s disease by restoring cellular energy ATP levels, preventing cellular alpha-synuclein aggregation, and decreasing ROS levels for neuroprotection. This multi-pronged approach may significantly slow disease progression. The encouraging results from our Phase I trial bring us one step closer to delivering a meaningful treatment option for PD patients worldwide.&#8221;<\/p>\n<p><b>About ENERGI-F705PD<\/b><\/p>\n<p>ENERGI-F705PD is a novel small-molecule drug delivered in an oral sustained-release formulation. It is designed to enhance cellular ATP and antioxidant production by engaging the purine salvage, glycolysis, and pentose phosphate pathways. This multi-pronged mechanism of action directly addresses key pathological hallmarks of Parkinson&#8217;s disease:<\/p>\n<ul type=\"disc\">\n<li><b>Reduce and Prevent Alpha-synuclein Aggregation:<\/b>\u00a0Elevated ATP acts as a hydrotrope, helping prevent the intracellular aggregation of misfolded alpha-synuclein, a central pathogenic hallmark of PD.<\/li>\n<li><b>Increase Reducing Power (antioxidant):<\/b>\u00a0ENERGI-F705PD upregulates the pentose phosphate pathway (PPP), leading to increased NADPH production and enhanced cellular antioxidant defense.<\/li>\n<li><b>Increase Tyrosine Hydroxylase Expression\/activity:<\/b>\u00a0By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD also enhances the expression and activity of tyrosine hydroxylase (TH), the key enzyme in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of PD patients.<\/li>\n<\/ul>\n<p><b>The Promise of Alpha-Synuclein Targeting in Parkinson&#8217;s Disease<\/b><\/p>\n<p>Parkinson&#8217;s disease, affecting over 10 million people globally, currently has no cure, with existing treatments only managing symptoms. The accumulation of alpha-synuclein protein is a key hallmark of the disease, making it a highly promising target for new disease-modifying therapies that aim to fundamentally change its progression. This critical area is seeing significant research and development, including both small molecules and antibody-based investigational treatments. ENERGI-F705PD, as an oral small-molecule drug, offers key advantages over antibody therapies, including better blood-brain barrier penetration, convenient oral administration, direct intracellular targeting, and potentially more accessible manufacturing.<\/p>\n<p><b>About Energenesis Biomedical<\/b><\/p>\n<p>Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that restore cellular energy and activate intrinsic repair mechanisms. By combining proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical aims to accelerate the development of treatments for unmet medical needs across various therapeutic areas, including neurodegenerative diseases, chronic wounds, and rare disorders.<\/p>\n<p>The company&#8217;s leading candidates include:<\/p>\n<ul type=\"disc\">\n<li>ENERGI-F705PD: Tablet for Parkinson&#8217;s disease (Preparing for Phase II)<\/li>\n<li>ENERGI-F703DFU: Gel for Diabetic foot ulcers (Phase III)<\/li>\n<li>ENERGI-F701: Tonic for Alopecia (Phase II completed)<\/li>\n<li>ENERGI-F703EB: Cream for Epidermolysis bullosa (EB), granted FDA Orphan Drug and Rare Pediatric Disease designation, and EMA orphan designation (Preparing for Phase II)<\/li>\n<\/ul>\n<p>For more information, please visit <a href=\"https:\/\/www.energenesis-biomedical.com\/en\" target=\"_blank\" rel=\"nofollow\">www.energenesis-biomedical.com\/en<\/a><\/p>\n<p>Contact: Business Development Team<\/p>\n<p><span>Email: <a href=\"mailto:partnership@energenesis-biomedical.com\" target=\"_blank\" rel=\"nofollow\">partnership@energenesis-biomedical.com<\/a><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<ul type=\"disc\">\n<li>The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational drug in 24 healthy subjects.<\/li>\n<li>The results confirmed the favorable safety and tolerability profile of ENERGI-F705PD and successfully validated its sustained-release oral formulation.<\/li>\n<li>Energenesis plans to advance ENERGI-F705PD into a Phase II trial.<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">TAIPEI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 1, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company focused on cellular energy restoration therapeutics, today announced the successful completion of its Phase I clinical trial for ENERGI-F705PD, an oral investigational drug candidate for Parkinson&#8217;s disease (PD). The Phase I study demonstrated favorable safety and tolerability in healthy volunteers, marking a significant milestone in the development of ENERGI-F705PD and reaffirming its potential as a disease-modifying therapy that targets intracellular alpha-synuclein aggregation. Energenesis Biomedical plans to submit a Phase II clinical trial application in 2025 to further evaluate the therapeutic efficacy of ENERGI-F705PD in patients with Parkinson&#8217;s disease.<\/p>\n<p>&#8220;Current treatments for Parkinson&#8217;s disease primarily target symptoms, while ENERGI-F705PD represents a novel therapeutic strategy with disease-modifying potential,&#8221; said <b>Dr. <span class=\"xn-person\">Han-Min Chen<\/span>, CEO &amp; Founder of Energenesis Biomedical<\/b>. &#8220;ENERGI-F705PD targets Parkinson&#8217;s disease by restoring cellular energy ATP levels, preventing cellular alpha-synuclein aggregation, and decreasing ROS levels for neuroprotection. This multi-pronged approach may significantly slow disease progression. The encouraging results from our Phase I trial bring us one step closer to delivering a meaningful treatment option for PD patients worldwide.&#8221;<\/p>\n<p><b>About ENERGI-F705PD<\/b><\/p>\n<p>ENERGI-F705PD is a novel small-molecule drug delivered in an oral sustained-release formulation. It is designed to enhance cellular ATP and antioxidant production by engaging the purine salvage, glycolysis, and pentose phosphate pathways. This multi-pronged mechanism of action directly addresses key pathological hallmarks of Parkinson&#8217;s disease:<\/p>\n<ul type=\"disc\">\n<li><b>Reduce and Prevent Alpha-synuclein Aggregation:<\/b>\u00a0Elevated ATP acts as a hydrotrope, helping prevent the intracellular aggregation of misfolded alpha-synuclein, a central pathogenic hallmark of PD.<\/li>\n<li><b>Increase Reducing Power (antioxidant):<\/b>\u00a0ENERGI-F705PD upregulates the pentose phosphate pathway (PPP), leading to increased NADPH production and enhanced cellular antioxidant defense.<\/li>\n<li><b>Increase Tyrosine Hydroxylase Expression\/activity:<\/b>\u00a0By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD also enhances the expression and activity of tyrosine hydroxylase (TH), the key enzyme in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of PD patients.<\/li>\n<\/ul>\n<p><b>The Promise of Alpha-Synuclein Targeting in Parkinson&#8217;s Disease<\/b><\/p>\n<p>Parkinson&#8217;s disease, affecting over 10 million people globally, currently has no cure, with existing treatments only managing symptoms. The accumulation of alpha-synuclein protein is a key hallmark of the disease, making it a highly promising target for new disease-modifying therapies that aim to fundamentally change its progression. This critical area is seeing significant research and development, including both small molecules and antibody-based investigational treatments. ENERGI-F705PD, as an oral small-molecule drug, offers key advantages over antibody therapies, including better blood-brain barrier penetration, convenient oral administration, direct intracellular targeting, and potentially more accessible manufacturing.<\/p>\n<p><b>About Energenesis Biomedical<\/b><\/p>\n<p>Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that restore cellular energy and activate intrinsic repair mechanisms. By combining proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical aims to accelerate the development of treatments for unmet medical needs across various therapeutic areas, including neurodegenerative diseases, chronic wounds, and rare disorders.<\/p>\n<p>The company&#8217;s leading candidates include:<\/p>\n<ul type=\"disc\">\n<li>ENERGI-F705PD: Tablet for Parkinson&#8217;s disease (Preparing for Phase II)<\/li>\n<li>ENERGI-F703DFU: Gel for Diabetic foot ulcers (Phase III)<\/li>\n<li>ENERGI-F701: Tonic for Alopecia (Phase II completed)<\/li>\n<li>ENERGI-F703EB: Cream for Epidermolysis bullosa (EB), granted FDA Orphan Drug and Rare Pediatric Disease designation, and EMA orphan designation (Preparing for Phase II)<\/li>\n<\/ul>\n<p>For more information, please visit <a href=\"https:\/\/www.energenesis-biomedical.com\/en\" target=\"_blank\" rel=\"nofollow\">www.energenesis-biomedical.com\/en<\/a><\/p>\n<p>Contact: Business Development Team<\/p>\n<p><span>Email: <a href=\"mailto:partnership@energenesis-biomedical.com\" target=\"_blank\" rel=\"nofollow\">partnership@energenesis-biomedical.com<\/a><\/span><\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-29290","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/29290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29290"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/29290\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}